Next Article in Journal
Design and Test of a Soft Plantar Force Measurement System for Gait Detection
Previous Article in Journal
Network Adaptive Deadband: NCS Data Flow Control for Shared Networks
Previous Article in Special Issue
Porous Bead-Based Diagnostic Platforms: Bridging the Gaps in Healthcare
Article Menu

Export Article

Open AccessReview
Sensors 2012, 12(12), 16614-16627; https://doi.org/10.3390/s121216614

Development of a Novel, Fully-Automated Genotyping System: Principle and Applications

1
ARKRAY Inc., Kyoto 602-0008, Japan
2
Division of Haematology, Respiratory Medicine, and Oncology, Faculty of Medicine, Saga University, Saga 849-8501, Japan
3
Saga Prefectural Hospital Koseikan, Saga 840-8571, Japan
*
Author to whom correspondence should be addressed.
Received: 15 May 2012 / Revised: 2 October 2012 / Accepted: 26 November 2012 / Published: 3 December 2012
(This article belongs to the Special Issue Micro and Nano Technologies for Point-of-Care Diagnosis)
Full-Text   |   PDF [611 KB, uploaded 21 June 2014]

Abstract

Genetic testing prior to treatment, pharmacogenetic analysis, is key to realizing personalized medicine which is a topic that has attracted much attention recently. Through the optimization of therapy selection and dosage, a reduction in side effects is expected. Genetic testing has been conducted as a type of pharmacogenetic analysis in recent years, but it faces challenges in terms of cost effectiveness and its complicated procedures. Here we report on the development of a novel platform for genetic testing, the i-densyTM, with the use of quenching probe system (QP-system) as principle of mutant detection. The i-densyTM automatically performs pre-treatment, PCR and detection to provide the test result from whole blood and extracted DNA within approximately 90 and 60 min, respectively. Integration of all steps into a single platform greatly reduces test time and complicated procedures. An even higher-precision genetic analysis has been achieved through the development of novel and highly-specific detection methods. The applications of items measured using the i-densyTM are diverse, from single nucleotide polymorphism (SNP), such as CYP2C19 and UGT1A1, to somatic mutations associated with cancer, such as EGFR, KRAS and JAK2. The i-densyTM is a useful tool for optimization of anticancer drug therapy and can contribute to personalized medicine. View Full-Text
Keywords: automated genotyping system; pharmacogenetic analysis; single nucleotide polymorphism; i-densyTM; Qprobe; mutation biased PCR; personalized medicine automated genotyping system; pharmacogenetic analysis; single nucleotide polymorphism; i-densyTM; Qprobe; mutation biased PCR; personalized medicine
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Suzuki, S.-I.; Komori, M.; Hirai, M.; Ureshino, N.; Kimura, S. Development of a Novel, Fully-Automated Genotyping System: Principle and Applications. Sensors 2012, 12, 16614-16627.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sensors EISSN 1424-8220 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top